Poolbeg Pharma (LON:POLB) Trading 10.1% Higher – Still a Buy?

Poolbeg Pharma PLC (LON:POLB)’s stock price traded up 10.1% during trading on Wednesday . The stock traded as high as GBX 5.84 and last traded at GBX 5.55. 5,824,547 shares were traded during trading, an increase of 359% from the average session volume of 1,268,309 shares. The stock had previously closed at GBX 5.04.

Wall Street Analyst Weigh In

Separately, Shore Capital Group reaffirmed a “house stock” rating on shares of Poolbeg Pharma in a research note on Tuesday.

Poolbeg Pharma Trading Up 3.4%

The stock has a market capitalization of £40.46 million, a P/E ratio of -6.10 and a beta of 1.78. The stock’s fifty day moving average price is GBX 4.46 and its two-hundred day moving average price is GBX 4.29.

Poolbeg Pharma (LON:POLB) last announced its quarterly earnings data on Tuesday, April 28th. The company reported GBX (0.94) earnings per share for the quarter. As a group, analysts expect that Poolbeg Pharma PLC will post -0.68 earnings per share for the current fiscal year.

About Poolbeg Pharma

Poolbeg Pharma plc (AIM: POLB) is a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field. The Company’s lead asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS). As such, POLB 001 could increase the number of patients that can receive these life-saving treatments, thereby increasing the market opportunity.